Oral buccoadhesive films of ondansetron: Development and evaluation

Kumria, Rachna; Gupta, Vishant; Bansal, Sanjay; Wadhwa, Jyoti; Nair, Anroop B.

doi:10.4103/2230-973x.114894

Cited by 33 publications

(23 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…HPMC K-100, Carbopol and Eudragit Õ NE 40 D based on their mucoadhesive/film forming/controlled release properties (Nair et al, 2007;Morales & McConville, 2011;Kumria et al, 2013). In order to understand the role of each polymer on film characteristics, the prepared films were grouped into three categories depending upon the polymer composition (Table 1).…”

Section: Mucoadhesion Studiesmentioning

confidence: 99%

Buccal films of prednisolone with enhanced bioavailability

Kumria¹,

Nair

Goomber

et al. 2014

Drug Delivery

Self Cite

View full text Add to dashboard Cite

The conventional formulation of prednisolone is considered to be low in efficacy, primarily on account of their failure in providing and maintaining effective therapeutic drug levels. This study aims to focus on development of a mucoadhesive buccal delivery system with a twofold objective of offering a rapid as well as a prolonged delivery of prednisolone coupled with enhanced therapeutic efficacy. Buccoadhesive films of prednisolone were prepared by solvent-casting method using hydroxyl propyl methyl cellulose (K100), Carbopol 940 and/or Eudragit NE 40 D. Placebo films possessing the most desirable physicomechanical properties were selected for drug loading. The effect of polymer and its content on film properties, i.e. mucoadhesive strength, swelling and hydration, in vitro drug release was studied. Based on these studies, film F7D was selected for ex vivo permeation across porcine cheek mucosa. The steady state flux of prednisolone across the buccal mucosa was found to be 105.33 ± 32.07 µg/cm(2)/h. A comparative pharmacokinetic study of prepared film (F7D) and oral suspension of prednisolone was conducted. In vivo data of buccal film show greater bioavailability (AUC0-α: 24.26 ± 4.06 µg.h/ml versus 10.65 ± 2.15 µg.h/ml) and higher Cmax (2.70 ± 0.38 µg/ml versus 2.29 ± 0.32 µg/ml) value when compared to oral suspension. The data observed from this study highlight the feasibility of the buccal route as a viable option for delivery of prednisolone.

show abstract

Section: Mucoadhesion Studiesmentioning

confidence: 99%

Buccal films of prednisolone with enhanced bioavailability

Kumria¹,

Nair

Goomber

et al. 2014

Drug Delivery

Self Cite

View full text Add to dashboard Cite

show abstract

“…They believe that surface charge density and flexibility of the chain are the major factors leading to high adhesion strength. Residence time also depends on the solubility rate of the applied polymers, and the presence of a hydrophobic polymer in the blend lengthens the mucoadhesion residence time [ [46], [74]]. Figure 16 represents residence time of chitosan/gelatin composite containing different ratios of keratin.…”

Section: Mucoadhesion Residence Timementioning

confidence: 99%

Development of chitosan/gelatin/keratin composite containing hydrocortisone sodium succinate as a buccal mucoadhesive patch to treat desquamative gingivitis

Davoudi

Rabiee

Houshmand

et al. 2017

Drug Development and Industrial Pharmacy

View full text Add to dashboard Cite

The aim of this research was to develop chitosan/gelatin/keratin composite containing hydrocortisone sodium succinate as a buccal mucoadhesive patch to treat desquamative gingivitis, which was fabricated through an environmental friendly process. Mucoadhesive films increase the advantage of higher efficiency and drug localization in the affected region. In this research, mucoadhesive films, for the release of hydrocortisone sodium succinate, were prepared using different ratios of chitosan, gelatin and keratin. In the first step, chitosan and gelatin proportions were optimized after evaluating the mechanical properties, swelling capacity, water uptake, stability, and biodegradation of the films. Then, keratin was added at different percentages to the optimum composite of chitosan and gelatin together with the drug. The results of surface pH showed that none of the samples were harmful to the buccal cavity. FTIR analysis confirmed the influence of keratin on the structure of the composite. The presence of a higher amount of keratin in the composite films resulted in high mechanical, mucoadhesive properties and stability, low water uptake and biodegradation in phosphate buffer saline (pH = 7.4) containing 10 U/ml lysozyme. The release profile of the films ascertained that keratin is a rate controller in the release of the hydrocortisone sodium succinate. Finally, chitosan/gelatin/keratin composite containing hydrocortisone sodium succinate can be employed in dental applications.

show abstract

“…Several groups have reported similar observations in drug release when polymer composition was varied. 24,25,28 At the end of our study, films Z1 and Z2 showed the slowest drug release, and, therefore, were excluded from further studies.…”

Section: As Indicated Inmentioning

confidence: 99%

In vitro and in vivo evaluation of nano-based films for buccal delivery of zolpidem

Al‐Dhubiab

2016

Braz. oral res.

View full text Add to dashboard Cite

In vitro and in vivo evaluation of nano-based films for buccal delivery of zolpidem Abstract: Insomnia is becoming increasingly prevalent in the world general population. Therapies used by patients include over-the-counter therapies, herbal and dietary supplements, and pharmacological or nonpharmacological treatments. Among these, zolpidem is a pharmacological treatment popularly used for insomnia. Zolpidem is well tolerated and especially efficacious for initiation of sleep, and therefore is effective for the treatment of sleep-onset insomnia. The purpose of the present study was to design and evaluate zolpidem nanoparticle-impregnated buccal films to prolong the duration of its action. Zolpidem nanospheres were prepared by double emulsion solvent evaporation and then loaded into buccoadhesive films (Z1-Z4) comprised of different concentrations of HPMC K100, Eudragit ® RL 100, and carbopol 974P. The prepared films were characterized for physicomechanical properties, mucoadhesion, percent hydration, in vitro drug release, ex vivo permeation, and in vivo studies. In vitro drug release was found to depend upon film composition. Ex vivo studies showed that film Z4 had the highest flux. In vivo studies revealed that administration of zolpidem nanosphere-impregnated film enhanced absorption of the drug (p < 0.0001), with a higher peak plasma concentration (52.54 ± 8.22 ng/mL) and area under the curve from time 0 to α (236.00 ± 39.51 ng.h/mL) than oral administration. The increase in time taken to reach the maximum drug concentration (1.5 h) further signifies the potential of these films to provide prolonged drug release. Given these promising results, we concluded that these buccal films could be an alternative route for effective zolpidem delivery.

show abstract

Oral buccoadhesive films of ondansetron: Development and evaluation

Cited by 33 publications

References 16 publications

Buccal films of prednisolone with enhanced bioavailability

Buccal films of prednisolone with enhanced bioavailability

Development of chitosan/gelatin/keratin composite containing hydrocortisone sodium succinate as a buccal mucoadhesive patch to treat desquamative gingivitis

In vitro and in vivo evaluation of nano-based films for buccal delivery of zolpidem

Contact Info

Product

Resources

About